期刊
CLINICAL & TRANSLATIONAL ONCOLOGY
卷 22, 期 7, 页码 989-1003出版社
SPRINGER INT PUBL AG
DOI: 10.1007/s12094-019-02218-4
关键词
ALK; Biomarkers; Non-small-cell lung cancer; EGFR; BRAF; PD-L1; ROS1
类别
In 2011 the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP) started a joint project to establish guidelines on biomarker testing in patients with advanced non-small-cell lung cancer (NSCLC) based on current evidence. As this field is constantly evolving, these guidelines have been updated, previously in 2012 and 2015 and now in 2019. Current evidence suggests that the mandatory tests to conduct in all patients with advanced NSCLC are forEGFRandBRAFmutations,ALKandROS1rearrangements and PD-L1 expression. The growing need to study other emerging biomarkers has promoted the routine use of massive sequencing (next-generation sequencing, NGS). The coordination of every professional involved and the prioritisation of the most suitable tests and technologies for each case remains a challenge.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据